NCT01721603View on ClinicalTrials.gov

Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
BRAFV600E Melanoma Patients
Interventions
DRUG

Dabrafenib

150 mg capsule by mouth twice daily

PROCEDURE

Gamma Knife Radiosurgery

This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.

DRUG

Trametinib

2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.

Trial Locations (1)

94115

University of San Francisco, California, San Francisco

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of California, San Francisco

OTHER